Compare CHMG & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHMG | RZLT |
|---|---|---|
| Founded | 1833 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.1M | 420.8M |
| IPO Year | 1995 | 2011 |
| Metric | CHMG | RZLT |
|---|---|---|
| Price | $81.13 | $4.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $57.00 | $9.67 |
| AVG Volume (30 Days) | 53.3K | ★ 1.9M |
| Earning Date | 04-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ 1.91 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.32 | N/A |
| Revenue Next Year | $9.13 | N/A |
| P/E Ratio | $39.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.61 | $1.07 |
| 52 Week High | $78.42 | $11.46 |
| Indicator | CHMG | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 68.15 | 53.68 |
| Support Level | $68.15 | $2.91 |
| Resistance Level | N/A | $5.42 |
| Average True Range (ATR) | 2.81 | 0.35 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 99.89 | 61.35 |
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.